Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9844578 | 0.74 | GLA (0.47) | GLATSHRALOX12NPSR1MEN1 | |
| SCHEMBL14300600 | 0.74 | GLA (0.60) | GLATSHRALOX12NPSR1MEN1 | |
| SCHEMBL22215688 | 0.72 | GLA (0.41) | GLATSHRALOX12NPSR1MEN1 | |
| SCHEMBL22215912 | 0.72 | PTGDR2 (0.38) | PTGDR2 | |
| SCHEMBL39101 | 0.71 | GLA (0.73) | GLATSHRALOX12NPSR1MEN1 | |
| SCHEMBL29464977 | 0.71 | GLA (0.73) | GLATSHRALOX12NPSR1MEN1 | |
| SCHEMBL17546526 | 0.71 | GLA (0.44) | GLATSHRALOX12NPSR1MEN1 | |
| SCHEMBL14557190 | 0.69 | GLA (0.70) | GLATSHRALOX12NPSR1MEN1 | |
| SCHEMBL14219663 | 0.68 | GLA (0.49) | GLATSHRALOX12NPSR1MEN1 | |
| SCHEMBL2498796 | 0.67 | GLA (0.48) | GLATSHRALOX12NPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773207-B2 | Thiol compound, method for synthesizing same, and uses for said thiol compound | SHIKOKU CHEMICALS CORPORATION (JP) | 2023-10-03 | — | — | US | disclosed |
| US-11773207-B2 | Thiol compound, method for synthesizing same, and uses for said thiol compound | SHIKOKU CHEMICALS CORPORATION (JP) | 2023-10-03 | — | — | US | disclosed |
| WO-2020145111-A1 | THIOL COMPOUND, METHOD FOR SYNTHESIZING SAME, AND USES FOR SAID THIOL COMPOUND | 四国化成工業株式会社 | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773207-B2 | Thiol compound, method for synthesizing same, and uses for said thiol compound | TST, TMT1A, CTH | GLA 4297/4885TSHR 3486/4885ALOX12 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.